 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||||| SOK583 (aflibercept biosimilar) / Sandoz
Trial completion: Mylight: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea (clinicaltrials.gov) - May 17, 2023
P3, N=485, Completed, Sponsor: Sandoz
Active, not recruiting --> Completed
- ||||| SOK583 (aflibercept biosimilar) / Sandoz
Enrollment closed: Mylight: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea (clinicaltrials.gov) - Jan 17, 2023
P3, N=485, Active, not recruiting, Sponsor: Sandoz
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || SOK583 (aflibercept biosimilar) / Novartis
Trial completion: Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit (clinicaltrials.gov) - Dec 12, 2022
P3, N=36, Completed, Sponsor: Sandoz
Recruiting --> Active, not recruiting Recruiting --> Completed
- | SOK583 (aflibercept biosimilar) / Novartis
Trial completion date, Trial primary completion date: Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit (clinicaltrials.gov) - Sep 15, 2022
P3, N=38, Recruiting, Sponsor: Sandoz
Recruiting --> Completed Trial completion date: Aug 2022 --> Nov 2022 | Trial primary completion date: Aug 2022 --> Nov 2022
- || SOK583 (aflibercept biosimilar) / Novartis
Trial completion: Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe (clinicaltrials.gov) - Jul 27, 2022
P3, N=30, Completed, Sponsor: Sandoz
Trial completion date: Aug 2022 --> Nov 2022 | Trial primary completion date: Aug 2022 --> Nov 2022 Not yet recruiting --> Completed
- || SOK583 (aflibercept biosimilar) / Novartis
Enrollment open: Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit (clinicaltrials.gov) - Jul 27, 2022
P3, N=38, Recruiting, Sponsor: Sandoz
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- ||| SOK583 (aflibercept biosimilar) / Sandoz
Trial completion date: Mylight: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea (clinicaltrials.gov) - Mar 29, 2022
P3, N=460, Recruiting, Sponsor: Sandoz
Not yet recruiting --> Recruiting Trial completion date: Jan 2024 --> Jul 2023
- |||| SOK583 (aflibercept biosimilar) / Novartis
New P3 trial: Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit (clinicaltrials.gov) - Mar 16, 2022
P3, N=38, Not yet recruiting, Sponsor: Sandoz
- ||| SOK583 (aflibercept biosimilar) / Sandoz
Trial completion date: Mylight: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea (clinicaltrials.gov) - Feb 22, 2022
P3, N=460, Recruiting, Sponsor: Sandoz
Trial completion date: Jan 2024 --> Jul 2023 Trial completion date: May 2023 --> Jan 2024
- |||| SOK583 (aflibercept biosimilar) / Novartis
New P3 trial: Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe (clinicaltrials.gov) - Dec 17, 2021
P3, N=30, Not yet recruiting, Sponsor: Sandoz
- |||||| SOK583 (aflibercept biosimilar) / Sandoz
Enrollment open: Mylight: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea (clinicaltrials.gov) - Jun 2, 2021
P3, N=460, Recruiting, Sponsor: Sandoz
Trial completion date: May 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- |||||||||| SOK583 (aflibercept biosimilar) / Sandoz
New P3 trial: Mylight: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea (clinicaltrials.gov) - Apr 28, 2021
P3, N=460, Not yet recruiting, Sponsor: Sandoz